Background NVX-CoV2373 is a recombinant severe acute respiratory coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant. Methods and findings The phase 2 component of our randomized, placebo-controlled, phase 1 to 2 trial was designed to identify which dosing regimen of NVX-CoV2373 should move forward into late-phase studies and was based on immunogenicity and safety data through Day 35 (14 days after the second dose). The trial was conducted at 9 sites in Australia and 8 sites in the United States. Participants in 2 age groups (aged 18 to 59 and 60 to 84 years) were randomly assigned to receive either 1 or 2 intramuscular doses of 5-μg or 25-μg NVX-CoV2373 or placebo, 21 days apart. Primary endpoints were immunoglobulin G (IgG) anti-spike protein response, 7-day solicited reactogenicity, and unsolicited adverse events. A key secondary endpoint was wild-type virus neutralizing antibody response. After enrollment, 1,288 participants were randomly assigned to 1 of 4 vaccine groups or placebo, with 1,283 participants administered at least 1 study treatment. Of these, 45% were older participants 60 to 84 years. Reactogenicity was predominantly mild to moderate in severity and of short duration (median <3 days) after first and second vaccination with NVX-CoV2373, with higher frequencies and intensity after second vaccination and with the higher dose. Reactogenicity occurred less frequently and was of lower intensity in older participants. Both 2-dose regimens of 5-μg and 25-μg NVX-CoV2373 induced robust immune responses in younger and older participants. For the 2-dose regimen of 5 μg, geometric mean titers (GMTs) for IgG anti-spike protein were 65,019 (95% confidence interval (CI) 55,485 to 76,192) and 28,137 (95% CI 21,617 to 36,623) EU/mL and for wild-type virus neutralizing antibody (with an inhibitory concentration of 50%—MN 50% ) were 2,201 (95% CI 1,343 to 3,608) and 981 (95% CI 560 to 1,717) titers for younger and older participants, respectively, with seroconversion rates of 100% in both age groups. Neutralizing antibody responses exceeded those seen in a panel of convalescent sera for both age groups. Study limitations include the relatively short duration of safety follow-up to date and current lack of immune persistence data beyond the primary vaccination regimen time point assessments, but these data will accumulate over time. Conclusions The study confirmed the phase 1 findings that the 2-dose regimen of 5-μg NVX-CoV2373 is highly immunogenic and well tolerated in younger adults. In addition, in older adults, the 2-dose regimen of 5 μg was also well tolerated and showed sufficient immunogenicity to support its use in late-phase efficacy studies. Trial registration ClinicalTrials.gov NCT04368988 . In a phase 2 randomized placebo-controlled trial, Neil Formica and coauthors investigate the immunogenicity and safety of different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine in younger and older adults in USA and Australia. Author summary Why was this study done? This study was designed to identify which dosing regimen of NVX-CoV2373 (1 or 2 doses of either 5 μg or 25 μg) was immunogenic and associated with a safety and tolerability profile that was acceptable to move forward into late-phase efficacy studies. What did the researchers do and find? Participants ( n = 1,288) in 2 age groups (aged 18 to 59 and 60 to 84 years) were randomly assigned to receive either 1 or 2 intramuscular doses of 5-μg or 25-μg NVX-CoV2373 or placebo. Reactogenicity was predominantly mild to moderate in severity and of short duration (median <3 days) after first and second vaccination with NVX-CoV2373, with higher frequencies and intensity after second vaccination and with the higher dose. Reactogenicity occurred less frequently and was of lower intensity in older participants. The 2-dose regimen of 5-μg NVX-CoV2373 was found to be immunogenic and well tolerated in both younger and older adults. What do these findings mean? These findings support the use of the lower-dose regimen in late-phase efficacy studies.
【초록키워드】 Treatment, neutralizing antibody, SARS-CoV-2, IgG, Efficacy, Vaccine, coronavirus, immune response, vaccination, immunogenicity, reactogenicity, Trial, Older adults, Phase 2, severity, Antibody Response, spike glycoprotein, Spike protein, adverse events, Randomized, Protein, Adults, Immunoglobulin G, Immunoglobulin, immune responses, spike glycoproteins, placebo-controlled trial, Mild, age, Placebo, Follow-up, United States, respiratory, USA, group, moderate, placebo-controlled, convalescent sera, Neutralizing antibody response, Anti-spike, immune persistence, Recombinant spike protein, Frequency, dose, NVX-CoV2373, regimen, Phase 1, mild to moderate, geometric mean, Support, intensity, Older, Tolerability, Participants, Enrollment, Endpoint, Trial registration, 95% CI, 95% confidence interval, secondary endpoint, assessments, primary endpoints, second vaccination, Matrix-M1 adjuvant, second dose, These data, geometric mean titers, GMTs, participant, neutralizing antibody responses, immunogenic, limitation, wild-type virus, randomized placebo-controlled trial, short duration, seroconversion rates, seroconversion rate, inhibitory concentration, safety follow-up, geometric mean titer, researcher, Administered, The United States, Respiratory Coronavirus, vaccine group, Randomly, trimeric, robust, identify, lack, include, composed, addition, Day, conducted, median, assigned, groups, accumulate, exceeded, receive, dose regimen, Formica, full-length SARS-CoV-2, intramuscular dose, occurred less, 【제목키워드】 SARS-CoV-2, Vaccine, Recombinant spike protein, Older, randomized placebo-controlled trial, dose regimen,